Sunil Healthcare Reports Mixed Q2 FY2026 Results with Standalone Profit and Consolidated Loss
Sunil Healthcare Limited announced its Q2 FY2026 results, showing a standalone profit but consolidated loss. Standalone revenue increased to Rs. 235.76 lakhs in Q2, with a profit of Rs. 7.90 lakhs. Half-yearly standalone revenue reached Rs. 461.96 lakhs with a profit of Rs. 50.75 lakhs. However, consolidated operations reported a Q2 loss of Rs. 5.64 lakhs and a half-year loss of Rs. 18.47 lakhs. The Board approved these results on November 4, 2025, with auditors Singhi & Co. conducting a limited review.

*this image is generated using AI for illustrative purposes only.
Sunil Healthcare Limited has announced its unaudited financial results for the second quarter and first half of the fiscal year 2025-26, revealing a mixed performance across its standalone and consolidated operations.
Standalone Performance
For the quarter ended September 30, 2025, Sunil Healthcare's standalone revenue from operations stood at Rs. 235.76 lakhs, showing a slight improvement from Rs. 226.20 lakhs in the previous quarter. The company reported a standalone profit after tax of Rs. 7.90 lakhs for Q2 FY2026.
On a half-yearly basis, the standalone revenue reached Rs. 461.96 lakhs, up from Rs. 437.52 lakhs in the corresponding period of the previous year. The standalone profit after tax for the half-year period was Rs. 50.75 lakhs.
Consolidated Results
While the standalone figures showed positive trends, the consolidated results painted a different picture. The company reported a consolidated loss after tax of Rs. 5.64 lakhs for Q2 FY2026. For the half-year period, the consolidated operations recorded a loss of Rs. 18.47 lakhs.
Financial Highlights
| Particulars | Q2 FY2026 (Standalone) | H1 FY2026 (Standalone) | Q2 FY2026 (Consolidated) | H1 FY2026 (Consolidated) |
|---|---|---|---|---|
| Revenue from Operations | 235.76 | 461.96 | - | - |
| Profit/(Loss) After Tax | 7.90 | 50.75 | (5.64) | (18.47) |
All figures in Rs. lakhs
Board Meeting and Auditor's Review
The company's Board of Directors convened on November 4, 2025, to approve these financial results. The meeting, which started at 4:20 p.m. and concluded at 6:25 p.m., also saw the approval of limited review reports from the auditors.
Singhi & Co., Chartered Accountants, conducted an independent review of both the standalone and consolidated financial results. Their review reports, dated November 4, 2025, state that nothing has come to their attention that causes them to believe that the financial statements are not prepared in accordance with applicable accounting standards and SEBI regulations.
The divergence between standalone profit and consolidated loss suggests that Sunil Healthcare's subsidiaries may be facing challenges. The performance of the company's foreign subsidiaries, Sunil Healthcare Mexico Sa De CV and Sunil Healthcare North America LLC, could be contributing factors to the consolidated loss.
As Sunil Healthcare navigates through these mixed results, stakeholders will be keen to see how the company addresses the challenges in its consolidated operations while building on the positive momentum in its standalone performance.
Historical Stock Returns for Sunil Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.37% | +4.05% | -7.54% | +4.70% | -13.99% | +155.07% |



























